1.Herbst RS，Bajorin DF，Bleiberg H，et al：Clinical Cancer Advances 2005：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology.Journal of Clinical Oncology，2006，24：190-205.

2.Ozols RF，Herbst RS，Colson YL，et al：Clinical Cancer Advances 2006：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology.Journal of Clinical Oncology，2006，25：146-162.

3.Gralow J，Ozols RF，Bajorin DF，et al：Clinical Cancer Advances 2007：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology.Journal of Clinical Oncology，2008，26：313-325.

4.Petrelli NJ，Winer EP，Brahmer J，et al：Clinical Cancer Advances 2009：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology.Journal of Clinical Oncology，2009，27：6052-6069.

5.Winer E，Gralow J，Diller L，et al：Clinical Cancer Advances 2008：Major Research Advances in Cancer Treatment，Prevention，and Screening—A Report From the American Society of Clinical Oncology.Journal of Clinical Oncology，2009，27：812-826.

6.Kris MG，Benowitz SI，Adams S，et al：Clinical Cancer Advances 2010：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.Journal of Clinical Oncology，2010，28：5327-5347.

7.Vogelzang NJ，Benowitz SI，Adams S，et al：Clinical Cancer Advances 2011：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.Journal of Clinical Oncology，2012，30：88-109.

8.Roth BJ，Krilov L，Adams S，et al：Clinical Cancer Advances 2012：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.Journal of Clinical Oncology，2013，31：131-161.

9.Patel JD，Krilov L，Adams S，et al：Clinical Cancer Advances 2013：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.Journal of Clinical Oncology，2014，32：129-160.

10.Masters GA，Krilov L，Bailey HH，et al：Clinical cancer advances 2015：Annual report on progress against cancer from the American Society of Clinical Oncology.J Clin Oncol，2015，33：786-809.

11.Dizon DS，Krilov L，Cohen E，et al：Clinical Cancer Advances 2016：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.J Clin Oncol，2016，34：987-1011.

12.Burstein HJ，Krilov L，Aragon-Ching JB，et al：Clinical Cancer Advances 2017：Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.J Clin Oncol：Jco，2017，2016715292.

13.Mok TS，Wu YL，Ahn MJ，et al：Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.N Engl J Med，2017，376：629-640.

14.Liu S，Wang R，Zhang Y，et al：Precise Diagnosis of Intraoperative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma.J Clin Oncol，2016，34：307-13.

15.Dai C，Shen J，Ren Y，et al：Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer </=1cm or >1 to 2cm Among Lobectomy，Segmentectomy，and Wedge Resection：A Population-Based Study.J Clin Oncol，2016，34：3175-82.

16.Cheng Y，et al.Randomized phase Ⅱ trial of gefitinib withand without pemetrexed as first-line therapy in patientswith advanced nonsquamous non-small-cell lung cancerwith activating epidermal growth factor receptor mutations.J Clin Oncol，2016，34：3258-3266.

17.Luo HY，Li YH，Wang W，et al：Single-agent capecitabine as maintenance therapy after induction of XELOX（or FOLFOX）in first-line treatment of metastatic colorectal cancer：randomized clinical trial of efficacy and safety.Ann Oncol，2016，27：1074-81.

18.Huang YQ，Liang CH，He L，et al：Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer.J Clin Oncol，2016，34：2157-64.

19.Hu Y，Huang C，Sun Y，et al：Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer：A Randomized Controlled Trial.J Clin Oncol，2016，34：1350-7.

20.Pan KF，Zhang L，Gerhard M，et al：A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County，China：baseline results and factors affecting the eradication.Gut，2016，65：9-18.

21.Harbeck N，Huang CS，Hurvitz S，et al：Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment（LUX-Breast 1）：an open-label，randomised，phase 3 trial.Lancet Oncol，2016，17：357-66.

22.Huang Z，Wen W，Zheng Y，et al：Breast cancer incidence and mortality：trends over 40 years among women in Shanghai，China.Ann Oncol，2016，27：1129-34.

23.Li X，Cui Y，Sun Z，et al：DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma：A Randomized Controlled，Multicenter，Open-label Study in China.Clin Cancer Res，2016，22：5223-5228.

24.Xu L，Wang J，Kim Y，et al：A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma.Oncoimmunology，2016，5：e1083671.

25.Wang M，Li Z，Chu H，et al：Genome-Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3.Cancer Res，2016，76：3277-84.

26.Zhang L，Huang Y，Hong S，et al：Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma：a multicentre，randomised，open-label，phase 3 trial.Lancet，2016，388：1883-1892.

27.Sun Y，Li WF，Chen NY，et al：Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma：a phase 3，multicentre，randomised controlled trial.Lancet Oncol，2016，17：1509-1520.